Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on multiple sclerosis and other nerve diseases

NCT ID NCT07304154

Recruiting now Disease control Sponsor: Kite, A Gilead Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This early-phase trial is testing a new treatment called KITE-363 for people with certain autoimmune nerve diseases that have not responded to standard therapies. KITE-363 is a type of CAR T-cell therapy that uses a patient's own immune cells, modified to target and attack faulty immune cells. The study includes people with multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy, and aims to check safety and find the right dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KITE-363 (a type of CAR T-cell therapy that targets CD19 and CD20 proteins on immune cells)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat autoimmune neurologic diseases like multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
What could go wrong
This is an early Phase 1 trial with only 52 participants, so safety and effectiveness are not yet proven. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and nervous system problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic inflammatory demyelinating polyradiculoneuropathy multiple sclerosis myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MULTIPLE SCLEROSIS MYASTHENIA GRAVIS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Columbia University Irving Medical Center

    RECRUITING

    New York, New York, 10032, United States

  • Concord Repatriation General Hospital

    RECRUITING

    Sydney, New South Wales, 2139, Australia

  • Corner Hawkesbury Road and Darcy Road

    RECRUITING

    Westmead, New South Wales, 2145, Australia

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

  • Hoag Memorial Hospital Presbyterian

    RECRUITING

    Newport Beach, California, 92663, United States

  • Jewish General Hospital

    RECRUITING

    Montreal, H3T 1E2, Canada

  • LDS Hospital - Intermountain Health

    RECRUITING

    Salt Lake City, Utah, 84143, United States

  • Stanford Neuroscience Health Center

    RECRUITING

    Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.